Synthetic bio company Asimov agreed to collaborate with Cytiva to provide customers with an integrated offering for optimized biologics production. Access includes Asimov’s CHO Edge cell line development platform and Cytiva’s HyClone™ media and feed solutions, along with Cytiva’s Fast Trak™ process development services.
“Central to this collaboration is the optimization of our CHO Edge System in Cytiva’s HyClone media and feed, enabling high titer across biologic formats,” said Alec Nielsen, PhD, co-founder and CEO of Asimov. “By integrating a cell line development capability into Cytiva’s biomanufacturing technologies, we can enhance customers’ production efficiency and accelerate their development timelines for critical therapeutics.”
“By combining Asimov’s integrated suite of cells, genetic tools, AI models, and software with our process development services, customers will have a cohesive path from development to commercialization,” added Ludovic Brellier, president, hardware solutions, Cytiva.
